Logo

Exscientia Signs AI Drug Discovery Collaboration with Merck KGaA to Discover Novel Small Molecule Drug Candidates

Share this

Exscientia Signs AI Drug Discovery Collaboration with Merck KGaA to Discover Novel Small Molecule Drug Candidates

Shots:

  • Exscientia will receive $20M up front & ~$674M upon achievement of development, regulatory, and sales-based milestones for all 3 initial programs along with royalties on product sales if Merck KGaA commercializes a therapeutic from one of the initial targets of the collaboration
  • The collaboration will use Exscientia’s AI-driven precision drug design and discovery capabilities and Merck KGaA’s disease expertise in oncology and neuroinflammation, clinical development capabilities, and global footprint to discover novel small molecule drug candidates
  • Both companies will identify additional targets in oncology and immunology or other mutually agreed disease areas

Ref: Businesswire | Image: Merck KGaA

Related News:- Dewpoint Therapeutics Collaborated with Novo Nordisk to Identify Small Molecule Drugs for Insulin Resistance and Diabetes Progression

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions